

GLAXOSMITHKLINE PLC
Form 6-K
April 13, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 13 April 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley
 b) Position/status Chief Executive Officer

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £14.4089 20
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2018-04-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor
 b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- President, Global
Manufacturing & Supply
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 12
April 2018, on shares held
through the Company's Share
Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£14.4089 77
n/a (single transaction)
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange
(XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
b) Position/status Chief Financial Officer
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

| | | | |
|----|---|--|-----------------|
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) £14.4089 n/a (single transaction) | Volume(s) 27 |
| d) | Aggregated information Aggregated volume Price | | |
| e) | Date of the transaction | 2018-04-12 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |

| | | | |
|---|---|--|-----------------|
| 1. Details of PDMR/person closely associated with them ('PCA') | | | |
| a) | Name | Mr N Hirons | |
| b) | Position/status | SVP, Global Ethics & Compliance | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | |
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | |
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. | |
| c) | Price(s) and volume(s) | Price(s) £14.4089 | Volume(s) 11 |
| d) | Aggregated information Aggregated volume Price | n/a (single transaction) | |

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £14.4089 | 87 |
| n/a (single transaction) | |
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial notification
- 2.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

| | |
|--------------------------|-----------|
| Price(s) | Volume(s) |
| £14.4089 | 87 |
| n/a (single transaction) | |
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2018-04-12
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels
President, Global
- b) Position/status Pharmaceuticals

- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

| | |
|--|--|
| | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. |
| b) Nature of the transaction | |
| c) Price(s) and volume(s) | Price(s) Volume(s) £14.4089 1 n/a (single transaction) |
| d) Aggregated information Aggregated volume Price | |
| e) Date of the transaction | 2018-04-12 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|--------------------|---------------------------|
| a) Name | Mr P C Thomson |
| b) Position/status | President, Global Affairs |

| | |
|---------------------------------------|----------------------|
| c) Initial notification/ amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|--|--|

| | |
|------------------------------|--|
| | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan. |
| b) Nature of the transaction | |

| | |
|---------------------------|---|
| c) Price(s) and volume(s) | Price(s) Volume(s) £14.4089 48 |
|---------------------------|---|

| | |
|--|--------------------------|
| d) Aggregated information Aggregated volume Price | n/a (single transaction) |
|--|--------------------------|

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £14.4089 | 62 |
| n/a (single transaction) | |
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 13, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc